Thallion kick starts anti-Shiga toxin programme with LFB deal
This article was originally published in Scrip
Executive Summary
Thallion Pharmaceuticals and LFB Biotechnologies have entered an agreement to develop and commercialise Thallion's Shigamabs for the treatment of Shiga toxin-producing Escherichia coli, or STEC, infections.